Clinical trial
Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV…
NCT00101257 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00101257 |
|---|---|
| Title | Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer |
| Official title | Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD4+ Antigen-Specific T Cell Clones for Patients With Advanced Ovarian Cancer |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Biological |
| Interventions | therapeutic autologous lymphocytes |
| Enrollment | 18 |
| Start date | Oct 1, 2004 |
| Completion | Mar 1, 2010 |
| First posted | Jan 10, 2005 |
| Last update posted | May 7, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: